UBS Group
BIOT

UBS Group’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

UBS Group’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,954
Closed -$19K – 11553
2022
Q3 		$19K Buy
1,954
+25
+1% +$247 ﹤0.01% 7494
2022
Q2 		$19K Buy
1,929
+970
+101% +$9.51K ﹤0.01% 6976
2022
Q1 		$9K Sell
959
-1,649
-63% -$16.2K ﹤0.01% 8613
2021
Q4 		$26K Buy
2,608
+1,135
+77% +$11.1K ﹤0.01% 7568
2021
Q3 		$14K Buy
+1,473
New +$14.3K ﹤0.01% 7623

Other funds holding BIOT

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
RA
RiverPark Advisors New York $219M AUM 14.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

UBS Group's BIOT Position: Q4 2022 in Review

UBS Group sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q4 2022, closing a stake of 1,954 shares — an estimated $19K sold.

UBS Group first reported a position in BIOT in Q3 2021 and held it in 5 quarters. The position peaked at $26K in Q4 2021. 68 funds tracked by Wall St. Rank hold BIOT as of Q4 2022.

  • UBS Group reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 1,954 Biotech Acquisition Company Class A Ordinary Shares shares in Q4 2022, an estimated $19K.
  • UBS Group first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q3 2021 and held it in 5 quarters.
  • UBS Group's Biotech Acquisition Company Class A Ordinary Shares position peaked at $26K in Q4 2021.
  • 68 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.